Analyst Review Alert: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Analysts are weighing in on how ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 7 analysts, with 2 outperform and 1 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 9.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.49 a share, which would compare with $-0.39 in the same quarter last year. They have a high estimate of $-0.41 and a low estimate of $-0.58. Revenue for the period is expected to total nearly $80.00K from $1,000.00 the year-ago period.

For the full year, 9.00 Wall Street analysts forecast this company would deliver earnings of -1.70 per share, with a high estimate of $-0.99 and a low estimate of $-1.95. It had reported earnings per share of $-1.63 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $27.86M versus 61.00K in the preceding year.

The analysts project the company to maintain annual growth of around 73.60% percent over the next five years as compared to an average growth rate of 12.91% percent expected for its competitors in the same industry.

Among the 10 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ACAD is $45.70 but some analysts are projecting the price to go as high as $54.00. If the optimistic analysts are correct, that represents a 61 percent upside potential from the recent closing price of $33.50. Some sell-side analysts, particularly the bearish ones, have called for $35.00 price targets on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) .

In the last reported results, the company reported earnings of $-0.39 per share, while analysts were calling for share earnings of $-0.33. It was an earnings surprise of -18.20%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Analyst Review Alert: Allergan plc Ordinary Shares (NYSE:AGN)

Analysts are weighing in on how Allergan plc Ordinary Shares (NYSE:AGN), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.9. The stock is rated as buy by 10 analysts, with 6 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 14.00 analysts offering adjusted EPS forecast have a consensus estimate of $3.38 a share, which would compare with $4.41 in the same quarter last year. They have a high estimate of $3.67 and a low estimate of $3.10. Revenue for the period is expected to total nearly $4.11B from $5.73B the year-ago period.

For the full year, 17.00 Wall Street analysts forecast this company would deliver earnings of 14.23 per share, with a high estimate of $14.78 and a low estimate of $13.70. It had reported earnings per share of $13.43 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $16.76B versus 15.07B in the preceding year.

The analysts project the company to maintain annual growth of around 11.85% percent over the next five years as compared to an average growth rate of 16.51% percent expected for its competitors in the same industry.

Among the 16 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for AGN is $292.63 but some analysts are projecting the price to go as high as $400.00. If the optimistic analysts are correct, that represents a 71 percent upside potential from the recent closing price of $233.51. Some sell-side analysts, particularly the bearish ones, have called for $232.00 price targets on shares of Allergan plc Ordinary Shares (NYSE:AGN).

In the last reported results, the company reported earnings of $4.41 per share, while analysts were calling for share earnings of $4.38. It was an earnings surprise of 0.70%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

Analyst Review Alert: Apache Corporation (NYSE:APA)

Analysts are weighing in on how Apache Corporation (NYSE:APA), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.8. The stock is rated as buy by 7 analysts, with 4 outperform and 18 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 26.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.39 a share, which would compare with $0.22 in the same quarter last year. They have a high estimate of $0.04 and a low estimate of $-1.25. Revenue for the period is expected to total nearly $1.23B from $1.98B the year-ago period.

For the full year, 28.00 Wall Street analysts forecast this company would deliver earnings of -1.07 per share, with a high estimate of $0.05 and a low estimate of $-3.45. It had reported earnings per share of $-0.34 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $5.09B versus 6.37B in the preceding year.

The analysts project the company to maintain annual growth of around -43.84% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 31 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for APA is $56.23 but some analysts are projecting the price to go as high as $67.00. If the optimistic analysts are correct, that represents a 15 percent upside potential from the recent closing price of $58.16. Some sell-side analysts, particularly the bearish ones, have called for $40.00 price targets on shares of Apache Corporation (NYSE:APA).

In the last reported results, the company reported earnings of $0.22 per share, while analysts were calling for share earnings of $-0.26. It was an earnings surprise of 184.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Apache Corporation, an independent energy company, explores, develops, and produces natural gas, crude oil, and natural gas liquids. It operates onshore and offshore assets primarily in the Permian Basin, the Anadarko basin in western Oklahoma, the Texas Panhandle, and Gulf Coast areas of the United States, as well as in Western Canada and Gulf of Mexico. The company also operates assets in Egypt and the United Kingdom in the North Sea. As of December 31, 2015, it had total estimated proved reserves of 794 million barrels of crude oil, 198 million barrels of natural gas liquids, and 3.4 trillion cubic feet of natural gas. Apache Corporation was founded in 1954 and is based in Houston, Texas.

Analyst Review Alert: Boeing Co (NYSE:BA)

Analysts are weighing in on how Boeing Co (NYSE:BA), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 5 analysts, with 4 outperform and 9 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 16.00 analysts offering adjusted EPS forecast have a consensus estimate of $2.15 a share, which would compare with $1.62 in the same quarter last year. They have a high estimate of $2.28 and a low estimate of $1.96. Revenue for the period is expected to total nearly $23.22B from $24.54B the year-ago period.

For the full year, 20.00 Wall Street analysts forecast this company would deliver earnings of 8.49 per share, with a high estimate of $8.82 and a low estimate of $8.27. It had reported earnings per share of $7.72 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $93.81B versus 96.11B in the preceding year.

The analysts project the company to maintain annual growth of around 10.45% percent over the next five years as compared to an average growth rate of 9.86% percent expected for its competitors in the same industry.

Among the 18 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for BA is $148.33 but some analysts are projecting the price to go as high as $196.00. If the optimistic analysts are correct, that represents a 47 percent upside potential from the recent closing price of $133.55. Some sell-side analysts, particularly the bearish ones, have called for $101.00 price targets on shares of Boeing Co (NYSE:BA).

In the last reported results, the company reported earnings of $1.62 per share, while analysts were calling for share earnings of $1.37. It was an earnings surprise of 18.20%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital. The Commercial Airplanes segment develops, produces, and markets commercial jet aircraft for various passenger and cargo requirements, as well as provides related support services to the commercial airline industry. This segment also offers aviation services support, aircraft modifications, spare parts, training, maintenance documents, and technical advice to commercial and government customers. The Boeing Military Aircraft segment is involved in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems for the global strike, vertical lift, and autonomous systems, as well as mobility, surveillance, and engagement. The Network & Space Systems segment engages in the research, development, production, and modification of electronics and information solutions; strategic missile and defense systems; space and intelligence systems; and space exploration products. The Global Services and Support segment offers integrated logistics, including supply chain management and engineering support; maintenance, modification, and upgrades for aircraft; and training systems and government services, such as pilot and maintenance training. The Boeing Capital segment facilitates, arranges, structures, and provides financing solutions, such as equipment under operating leases, finance leases, notes and other receivables, assets held for sale or re-lease, and investments. The Boeing Company was founded in 1916 and is based in Chicago, Illinois.

Analyst Review Alert: CenterPoint Energy, Inc. (NYSE:CNP)

Analysts are weighing in on how CenterPoint Energy, Inc. (NYSE:CNP), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.6. The stock is rated as buy by 2 analysts, with 3 outperform and 9 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 6.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.19 a share, which would compare with $0.19 in the same quarter last year. They have a high estimate of $0.23 and a low estimate of $0.12. Revenue for the period is expected to total nearly $1.62B from $1.53B the year-ago period.

For the full year, 14.00 Wall Street analysts forecast this company would deliver earnings of 1.14 per share, with a high estimate of $1.17 and a low estimate of $1.03. It had reported earnings per share of $1.10 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $7.75B versus 7.39B in the preceding year.

The analysts project the company to maintain annual growth of around 5.60% percent over the next five years as compared to an average growth rate of 6.59% percent expected for its competitors in the same industry.

Among the 12 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CNP is $22.54 but some analysts are projecting the price to go as high as $26.00. If the optimistic analysts are correct, that represents a 11 percent upside potential from the recent closing price of $23.49. Some sell-side analysts, particularly the bearish ones, have called for $19.00 price targets on shares of CenterPoint Energy, Inc. (NYSE:CNP).

In the last reported results, the company reported earnings of $0.19 per share, while analysts were calling for share earnings of $0.19. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

CenterPoint Energy, Inc. operates as a public utility holding company in the United States. The companys Electric Transmission & Distribution segment offers electric transmission and distribution services to retail electric providers, municipalities, electric cooperatives, and other distribution companies. As of December 31, 2015, this segment owned 28,474 pole miles of overhead distribution lines and 3,723 circuit miles of overhead transmission lines; 23,120 circuit miles of underground distribution lines and 26 circuit miles of underground transmission lines; and 232 substations with a capacity of 58,674 megavolt amperes. Its Natural Gas Distribution segment sells regulated intrastate natural gas; provides natural gas transportation and storage services for residential, commercial, industrial, and transportation customers; and offers unregulated services comprising residential appliance repair and maintenance services, as well as sells heating, ventilating and air conditioning equipment. This segment owned approximately 74,000 linear miles of natural gas distribution mains. The companys Energy Services segment provides physical natural gas supplies primarily to commercial and industrial customers, and electric and gas utilities; natural gas management services; and physical delivery services, as well as procures and optimizes transportation and storage assets. It owns and operates approximately 200 miles of intrastate pipelines; and leases transportation capacity on various interstate and intrastate pipelines, and storage. Its Midstream Investments segment provides gathering, processing, compression, treating, dehydration, and natural gas liquids fractionation for producer customers. This segment had approximately 12,400 miles of gathering pipelines, 7,900 miles of interstate pipelines, and approximately 2,300 miles of intrastate pipelines. The company was founded in 1882 and is headquartered in Houston, Texas.

Analyst Review Alert: Community Health Systems (CYH)

Analysts are weighing in on how Community Health Systems (NYSE:CYH), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.9. The stock is rated as buy by 2 analysts, with 2 outperform and 14 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 22.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.58 a share, which would compare with $1.14 in the same quarter last year. They have a high estimate of $0.90 and a low estimate of $0.39. Revenue for the period is expected to total nearly $4.52B from $4.88B the year-ago period.

For the full year, 21.00 Wall Street analysts forecast this company would deliver earnings of 2.24 per share, with a high estimate of $2.67 and a low estimate of $1.46. It had reported earnings per share of $3.23 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $18.12B versus 19.44B in the preceding year.

The analysts project the company to maintain annual growth of around 5.72% percent over the next five years as compared to an average growth rate of 14.88% percent expected for its competitors in the same industry.

Among the 19 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CYH is $16.55 but some analysts are projecting the price to go as high as $26.00. If the optimistic analysts are correct, that represents a 87 percent upside potential from the recent closing price of $13.89. Some sell-side analysts, particularly the bearish ones, have called for $10.50 price targets on shares of Community Health Systems (NYSE:CYH).

In the last reported results, the company reported earnings of $1.14 per share, while analysts were calling for share earnings of $0.89. It was an earnings surprise of 28.10%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Community Health Systems, Inc., together with its subsidiaries, owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers, ambulatory surgery centers, and home health and hospice agencies. In addition, it offers management and consulting services to non-affiliated general acute care hospitals. As of February 15, 2016, the company owned, leased, or operated 195 affiliated hospitals in 29 states with approximately 30,000 licensed beds. Community Health Systems, Inc. was founded in 1985 and is headquartered in Franklin, Tennessee.

Analyst Review Alert: CSX Corp. (NASDAQ:CSX)

Analysts are weighing in on how CSX Corporation (NASDAQ:CSX), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 6 analysts, with 8 outperform and 11 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 26.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.45 a share, which would compare with $0.56 in the same quarter last year. They have a high estimate of $0.50 and a low estimate of $0.41. Revenue for the period is expected to total nearly $2.72B from $3.06B the year-ago period.

For the full year, 29.00 Wall Street analysts forecast this company would deliver earnings of 1.75 per share, with a high estimate of $1.89 and a low estimate of $1.60. It had reported earnings per share of $2.00 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $10.87B versus 11.81B in the preceding year.

The analysts project the company to maintain annual growth of around 5.82% percent over the next five years as compared to an average growth rate of 7.91% percent expected for its competitors in the same industry.

Among the 23 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CSX is $27.70 but some analysts are projecting the price to go as high as $31.00. If the optimistic analysts are correct, that represents a 15 percent upside potential from the recent closing price of $27.00. Some sell-side analysts, particularly the bearish ones, have called for $18.00 price targets on shares of CSX Corporation (NASDAQ:CSX).

In the last reported results, the company reported earnings of $0.56 per share, while analysts were calling for share earnings of $0.53. It was an earnings surprise of 5.70%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

CSX Corporation, together with its subsidiaries, provides rail-based transportation services in the United States and Canada. The company offers rail services, as well as transports intermodal containers and trailers. It transports agricultural products, phosphates and fertilizers, food and consumer products, chemicals, automotive products, metals, forest products, minerals, and waste and equipment; and coal, coke, and iron ore to electricity-generating power plants, steel manufacturers, and industrial plants. The company also exports coal to deep-water port facilities. In addition, it offers intermodal transportation services through a network of approximately 50 terminals transporting manufactured consumer goods in containers in the eastern United States; drayage services, including the pickup and delivery of intermodal shipments; and trucking dispatch services. Further, the company serves the automotive industry with distribution centers and storage locations, as well as connects non-rail served customers through transferring products from rail to trucks, which includes plastics and ethanol. Additionally, it acquires, develops, sells, leases, and manages real estate properties. The company operates approximately 21,000 route mile rail network, which serves various population centers in 23 states east of the Mississippi River, the District of Columbia, and the Canadian provinces of Ontario and Quebec, as well as owns and leases approximately 4,500 locomotives. It also serves production and distribution facilities through track connections. CSX Corporation was founded in 1978 and is based in Jacksonville, Florida.

Analyst Review Alert: Duke Realty Corp (NYSE:DRE)

Analysts are weighing in on how Duke Realty Corp (NYSE:DRE), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 4 analysts, with 3 outperform and 9 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 14.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.30 a share, which would compare with $0.28 in the same quarter last year. They have a high estimate of $0.31 and a low estimate of $0.29. Revenue for the period is expected to total nearly $202.25M from $202.00M the year-ago period.

For the full year, 15.00 Wall Street analysts forecast this company would deliver earnings of 1.19 per share, with a high estimate of $1.21 and a low estimate of $1.16. It had reported earnings per share of $1.17 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $806.76M versus 816.06M in the preceding year.

The analysts project the company to maintain annual growth of around 3.80% percent over the next five years as compared to an average growth rate of 15.72% percent expected for its competitors in the same industry.

Among the 15 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for DRE is $24.37 but some analysts are projecting the price to go as high as $28.00. If the optimistic analysts are correct, that represents a 10 percent upside potential from the recent closing price of $25.44. Some sell-side analysts, particularly the bearish ones, have called for $21.00 price targets on shares of Duke Realty Corp (NYSE:DRE).

In the last reported results, the company reported earnings of $0.28 per share, while analysts were calling for share earnings of $0.29. It was an earnings surprise of -3.40%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Duke Realty Corporation is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It offers a single point of responsibility for all aspects of a project, including leasing, asset management, construction and development. The firm primarily invests in commercial real estate sector. It was founded in 1972 and is headquartered in Indianapolis, Indiana with additional offices in Atlanta, Georgia; Baltimore, Maryland; Central Florida; Chicago, Illinois; Cincinnati, Ohio; Columbus, Ohio; Dallas, Texas; Houston, Texas; Minneapolis, Minnesota; Nashville, Tennessee; New Jersey; Northern and Southern California; Pennsylvania; Phoenix, Arizona; Raleigh, North Carolina; St. Louis, Missouri; Savannah, Georgia; Seattle, Washington; Washington D.C.; and South Florida.

Analyst Review Alert: Eli Lilly and Co (NYSE:LLY)

Analysts are weighing in on how Eli Lilly and Co (NYSE:LLY), might perform in the near term. Wall Street analysts have a  assessment of the stock, with a mean rating of 2.0. The stock is rated as buy by 9 analysts, with 7 outperform and 6 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 17.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.86 a share, which would compare with $0.90 in the same quarter last year. They have a high estimate of $0.92 and a low estimate of $0.78. Revenue for the period is expected to total nearly $5.14B from $4.98B the year-ago period.

For the full year, 21.00 Wall Street analysts forecast this company would deliver earnings of 3.57 per share, with a high estimate of $3.60 and a low estimate of $3.52. It had reported earnings per share of $3.43 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $20.91B versus 19.96B in the preceding year.

The analysts project the company to maintain annual growth of around 12.46% percent over the next five years as compared to an average growth rate of 16.51% percent expected for its competitors in the same industry.

Among the 21 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for LLY is $95.71 but some analysts are projecting the price to go as high as $116.00. If the optimistic analysts are correct, that represents a 57 percent upside potential from the recent closing price of $73.94. Some sell-side analysts, particularly the bearish ones, have called for $78.00 price targets on shares of Eli Lilly and Co (NYSE:LLY).

In the last reported results, the company reported earnings of $0.90 per share, while analysts were calling for share earnings of $0.74. It was an earnings surprise of 21.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Analyst Review Alert: First Majestic Silver Corp (NYSE:AG)

Analysts are weighing in on how First Majestic Silver Corp (NYSE:AG), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.8. The stock is rated as buy by 2 analysts, with 0 outperform and 2 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 4.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.02 a share, which would compare with $-0.03 in the same quarter last year. They have a high estimate of $0.05 and a low estimate of $0.00. Revenue for the period is expected to total nearly $69.00M from $54.19M the year-ago period.

For the full year, 4.00 Wall Street analysts forecast this company would deliver earnings of 0.10 per share, with a high estimate of $0.17 and a low estimate of $0.02. It had reported earnings per share of $-0.11 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $294.43M versus 219.44M in the preceding year.

The analysts project the company to maintain annual growth of around 46.80% percent over the next five years as compared to an average growth rate of 24.85% percent expected for its competitors in the same industry.

Among the 5 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for AG is $10.30 but some analysts are projecting the price to go as high as $13.17. If the optimistic analysts are correct, that represents a 6 percent upside potential from the recent closing price of $12.40. Some sell-side analysts, particularly the bearish ones, have called for $6.20 price targets on shares of First Majestic Silver Corp (NYSE:AG).

In the last reported results, the company reported earnings of $-0.03 per share, while analysts were calling for share earnings of $-0.02. It was an earnings surprise of -50.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

First Majestic Silver Corp. engages in the acquisition, exploration, development, and production of mineral properties with a focus on silver projects in Mexico. The company owns and operates six silver producing mines, including the La Encantada Mine, La Parrilla Mine, Del Toro Mine, San Martin Mine, La Guitarra Mine, and Santa Elena Mine. It also holds interests in the Plomosas silver project situated in Sinaloa State; La Luz silver project located in San Luis Potosi State; and Jalisco group of properties located in various mining districts in Jalisco, Mexico. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was founded in 1979 and is headquartered in Vancouver, Canada.